Printer Friendly

Report Published: Nociceptin Receptor - Pipeline Review, H1 2016.

[ClickPress, Wed Jun 08 2016]

Global Markets Direct's, 'Nociceptin Receptor (Kappa-Type 3 Opioid Receptor or KOR-3 or Orphanin FQ Receptor or OPRL1 or OOR or ORL1) - Pipeline Review, H1 2016', provides in depth analysis on Nociceptin Receptor (Kappa-Type 3 Opioid Receptor or KOR-3 or Orphanin FQ Receptor or OPRL1 or OOR or ORL1) targeted pipeline therapeutics.

The report provides comprehensive information on the Nociceptin Receptor (Kappa-Type 3 Opioid Receptor or KOR-3 or Orphanin FQ Receptor or OPRL1 or OOR or ORL1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Nociceptin Receptor (Kappa-Type 3 Opioid Receptor or KOR-3 or Orphanin FQ Receptor or OPRL1 or OOR or ORL1) targeted therapeutics development and features dormant and discontinued projects.

Full Report Details at

-

http://www.fastmr.com/prod/1175777_nociceptin_receptor_kappatype.aspx?afid=301

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

* The report provides a snapshot of the global therapeutic landscape for Nociceptin Receptor (Kappa-Type 3 Opioid Receptor or KOR-3 or Orphanin FQ Receptor or OPRL1 or OOR or ORL1)

* The report reviews Nociceptin Receptor (Kappa-Type 3 Opioid Receptor or KOR-3 or Orphanin FQ Receptor or OPRL1 or OOR or ORL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

* The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

Copyright [c] 2016 ClickPress Provided by SyndiGate Media Inc. ( Syndigate.info ).
COPYRIGHT 2016 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:ClickPress
Date:Jun 8, 2016
Words:492
Previous Article:"DC-DC Converter Market for Space - Global Forecast to 2020" now available at Fast Market Research.
Next Article:New Report Available: Sickle Cell Disease - Pipeline Review, H1 2016.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters